GlassScriptPhysician profile
Kausalya Pendyal
NPI 1831188119
$6,896.43
in general payments reported to CMS, 2019-2025
44 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $82.80 · 2021: $312 · 2022: $1,117 · 2023: $1,377 · 2024: $1,754 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,809.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $993.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $789.20 | 2021-2025 | |
| Pfizer INC. | $775.16 | 2019-2025 | |
| Lilly USA, LLC | $767.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $728.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.38 | 2019-2025 | Jardiance |
| Abbott Laboratories | $218.13 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.93 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $210.48 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $208.24 | 2022-2025 | Rexulti |
| Amgen INC. | $178.86 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $158.83 | 2022 | |
| Dynavax Technologies Corporation | $130.77 | 2022-2025 | Heplisav-B |
| Dexcom, INC. | $128.79 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $122.11 | 2019-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $111.86 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $108.58 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $85.88 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $83.81 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $70.40 | 2019-2024 | Capvaxive |
| Phadia US INC. | $46.18 | 2024-2025 | Immunocap |
| Esperion Therapeutics, INC. | $43.93 | 2022-2025 | Nexletol |
| Horizon Therapeutics Plc | $37.51 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $35.77 | 2025 | Ajovy |
| Eisai INC. | $33.14 | 2021-2025 | |
| Edwards Lifesciences Corporation | $32.87 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shield Therapeutics INC | $29.62 | 2024 | |
| Ardelyx, INC. | $29.09 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $28.64 | 2024 | Watchman Flx |
| Medtronic, INC. | $26.13 | 2025 | Inceptiv |
| Enterra Medical, INC. | $22.88 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.36 | 2024 | Gvoke Hypopen |
| Impulse Dynamics (USA) INC. | $19.15 | 2023 | Optimizer |
| Amarin Pharma, INC. | $17.74 | 2019 | |
| Axsome Therapeutics, INC. | $17.22 | 2025 | Sunosi |
| Viatris Specialty LLC | $16.97 | 2025 | Yupelri |
| Tms Neurohealth Centers INC. | $16.29 | 2025 | Tms Neurohealth Centers INC. |
| Medtronic Minimed, INC. | $15.63 | 2019 | |
| Exeltis, USA INC. | $15.07 | 2024 | Slynd |
| Pulmonx Corporation | $14.98 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Janssen Pharmaceuticals, INC | $13.72 | 2024 | Xarelto |
| Sanofi Pasteur INC. | $13.55 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.20 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kausalya Pendyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.